BioMedNewsBreaks – AnPac Bio-Medical Science Co. Ltd. (NASDAQ: ANPC) Files for Registration Testing of Its Multicancer CDA Device

August 23, 2021 09:40:22

AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in China and the United States, has filed with China’s National Medical Products Administration (“NMPA”) for registration testing of its class III, multicancer detection medical device; the device, which has been tested and evaluated extensively, features AnPac’s proprietary Cancer Differentiation Analysis Technology (“CDA”). The company has reported that all preclinical trials and tests conducted through July 2021 have produced positive results. Approval of the NMPA application would allow the device to be used to assist in the diagnosis of 11 different types of cancer, including lung, esophageal, gastric, rectal, colon, liver, breast, cervical, thyroid, pancreatic and brain cancers. The filing also includes a number of cancer types that do not yet have generally accepted biomarkers. The company anticipates that after registration testing of the CDA device, clinical trials at multiple hospitals will start in 2022. “We are extremely pleased with our current achievements and this significant progress in the commercialization efforts of our multicancer CDA technology,” said AnPac Bio CEO and chair Dr. Chris Yu. “Successful completion of this preclinical study for our CDA device and reaching the registration testing stage is a major milestone. This multicancer detection medical device is an important product of our company that we believe has significant advantages over currently marketed technologies. Once this medical device is approved for commercialization by the NMPA, it will also be an important revenue source for AnPac Bio, and we believe that it has considerable market potential. We will continue to accelerate the product registration process for this medical device, as well as work towards marketing our CDA-based tests as Laboratory Developed Tests (‘LDTs’) in the U.S.”

To view the full press release, visit

About AnPac Bio-Medical Science Co. Ltd.

AnPac Bio is a biotechnology company focused on early cancer screening and detection, with 142 issued patents as of March 31, 2021. With two certified clinical laboratories in China and one CLIA-registered clinical laboratory in the United States, AnPac Bio performs a suite of cancer screening and detection tests, including Cancer Differentiation Analysis (“CDA”), biochemical, immunological and genomics tests. According to Frost & Sullivan, AnPac Bio ranked third worldwide among companies offering next-generation early cancer screening and detection technologies in terms of the number of clinical samples for cancer screening and detection in 2019. The company has a significant cancer screening and detection database consisting of approximately 43,900 clinical samples as of March 31, 2021.

AnPac Bio’s CDA technology platform has been shown in retrospective validation studies to be able to detect the risk of more than 20 different cancer types with high sensitivity and specificity. For more information about the company, visit

NOTE TO INVESTORS: The latest news and updates relating to ANPC are available in the company’s newsroom at

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:

BioMedWire (BMW)
San Francisco, California
415.949.5050 Office

BioMedWire is part of the InvestorBrandNetwork